Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Horita, Yosuke; Nishino, Michiko; Sugimoto, Saiho; Kida, Akihiko; Mizukami, Atsuyoshi; Yano, Masaaki; Arihara, Fumitaka; Matsuda, Koichiro; Matsuda, Mitsuru; Sakai, Akito
• Is Part Of: Anti-cancer drugs. Volume 30:Issue 1(2019)
• Publication Date: 2019-01
• Subjects: gastric cancer -- paclitaxel -- second-line chemotherapy -- trastuzumab; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000691
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Background: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy. We evaluated the efficacy and safety of weekly paclitaxel plus Tmab as second-line chemotherapy for HER2-positive gastric cancer patients. Patients and methods: Eligible patients were older than or equal to 20 years, had histologically confirmed gastric adenocarcinoma that was HER2 positive (immunohistochemistry 3+ or immunohistochemistry 2+ and fluorescence in-situ hybridization positive or dual color in-situ hybridization positive), and had been treated previously with chemotherapy (pretreated or not with Tmab). Patients received weekly paclitaxel plus Tmab as the second-line chemotherapy. The primary endpoint was the overall response rate (ORR; threshold ORR=20% and expected ORR=35%). Results: Twenty-eight patients were enrolled. ORR was 21.4%. The median progression-free survival (PFS) was 4.6 months. The median overall survival (OS) was 9.6 months. No significant differences were observed in ORR, PFS, or OS between the Tmab beyond progression (TBP) group ( n =20) and the non-TBP group ( n =8). However, in the TBP group, a therapeutic effect was associated with the duration of PFS in the first-line Tmab treatment [≥6 months PFS in the first-line Tmab treatment ( n =10) vs. <6 months ( n =10); ORR: 40 and 10%, P =0.303, PFS: 6.2 and 2.8 months, P =0.005, OS: 15.8 and 6.5 months, P =0.006, respectively]. Conclusion: Weekly paclitaxel plus Tmab was not superior as second-line chemotherapy for HER2-positive gastric cancer patients, but may be effective for patients who showed better responses to Tmab-combined chemotherapy in the first-line treatment.